Last updated: 2026-10-07 15:39:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
aTyr Pharma, Inc. (ATYR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $0,28, with a market capitalization of $28,45M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,27 to $1,12. This page covers its latest market performance, valuation, price trends and company information.
$28,45M | |
$0,28 | |
$7,29 | |
$0,27 | |
$0,28 | |
257,97K | |
3,25M | |
-- | |
$1,12 | |
$0,27 | |
-- | |
-- |
aTyr Pharma, Inc. (ATYR) is currently trading at $0,28 as of 2026-10-07 15:34:00, up 0,21% ($0,00) from the previous close of $0,28
During today's regular trading session, ATYR has traded between $0,27 and $7,29, with a trading volume of 257,97K shares. The current price is near the lower end of today's range.
Over the past seven days, aTyr Pharma, Inc. (ATYR) moved from $0,30 to $0,28, representing a decline of 4,60% ($0,01).
The stock traded between $0,27 and $0,32 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2,40 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2,2%
ATYR is currently trading at $0,28, placing it 2,2% of the way from its 52-week low of $0,27 to its 52-week high of $1,12. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 58 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of aTyr Pharma, Inc. (ATYR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.